Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3eeb3ba1c10701bdc91e9a2f2d66a2cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff81a650b70e913d3b2524b45e4c7320 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7890dd06821659260c0ec965a05d6570 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fee896617d6bc402607c5a8588e8b80 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2010-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b35cd9e5a9d084494f7d50c6349ad194 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b24b6a30bf2ed1cb438dcee33da7a083 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f7f4872d1b142a750ae0af2d8489d37 |
publicationDate |
2010-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2010108192-A1 |
titleOfInvention |
Mirnas as therapeutic targets in cancer |
abstract |
Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate, mi- 140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013065769-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012145743-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8765707-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012084709-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103243091-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103243091-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9939442-B2 |
priorityDate |
2009-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |